Advertisement
Screener

Pluri Inc. (PLUR) Overview

Pluri Inc. (PLUR) Overview

  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.55; Beat / miss (m).
  • 1 Oct 2025: Period ending 31 Dec 2025; Estimate (m); Actual -0.71; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -0.65; Beat / miss (m).
  • 1 Jan 2025: Period ending 31 Mar 2025; Estimate (m); Actual -0.94; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$0.92$1.29$1.80$2.52$3.53$4.942025-09-292026-09-29$0.92$1.80$3.51$6.84$13.35$26.042021-09-292026-09-29$0.92$2.61$7.39$20.94$59.31$168.002016-09-292026-09-29$0.92$4.49$21.84$106.33$517.63$2,520.002006-09-292026-09-29$0.92$7.41$59.66$480.05$3,862.64$31,080.002003-06-302026-09-29

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$1.01
Previous close
$0.97
Change
$0.04
Change (%)
4.12%
Close date
2026-09-29
Previous close date
2026-09-28
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

PLUR
-66.22%
S&P 500
(m)

1 year

PLUR
-78.09%
S&P 500
(m)

3 years

PLUR
-78.96%
S&P 500
(m)

5 years

PLUR
-95.24%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

31 Mar 2026 ○ Estimate (m) ● Actual -0.55

-1.02-0.85-0.69-0.52-0.3531 Dec 2024: estimate (m); actual -0.5331 Dec 2024(m)31 Mar 2025: estimate (m); actual -0.9431 Mar 2025(m)30 Sept 2025: estimate (m); actual -0.6530 Sept 2025(m)31 Dec 2025: estimate (m); actual -0.7131 Dec 2025(m)31 Mar 2026: estimate (m); actual -0.5531 Mar 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202631 Mar 2026(m)-0.55(m)(m)
1 Oct 202531 Dec 2025(m)-0.71(m)(m)
1 Jul 202530 Sept 2025(m)-0.65(m)(m)
1 Jan 202531 Mar 2025(m)-0.94(m)(m)
1 Oct 202431 Dec 2024(m)-0.53(m)(m)

30 Jun 2026 ○ Estimate (m) ● Actual -2.44

-6.32-5.02-3.71-2.40-1.1030 Jun 2022: estimate (m); actual -1.2830 Jun 2022(m)30 Jun 2023: estimate (m); actual -6.2430 Jun 2023(m)30 Jun 2024: estimate (m); actual -3.9930 Jun 2024(m)30 Jun 2025: estimate (m); actual -3.5630 Jun 2025(m)30 Jun 2026: estimate (m); actual -2.4430 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jul 202530 Jun 2026(m)-2.44(m)(m)
1 Jul 202430 Jun 2025(m)-3.56(m)(m)
1 Jul 202330 Jun 2024(m)-3.99(m)(m)
1 Jul 202230 Jun 2023(m)-6.24(m)(m)
1 Jul 202130 Jun 2022(m)-1.28(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 0.34M* ■ Earnings -5.88M* — Profit margin -1755.22%*

-7.37M-3323.2%-4.53M-2800.2%-1.68M-2277.2%1.16M-1754.2%30 Sept 2025: revenue 0.32M; earnings -5.85M; profit margin -1851.27%30 Sept 202531 Dec 2025: revenue 0.20M; earnings -6.54M; profit margin -3304.55%31 Dec 202531 Mar 2026: revenue 0.17M; earnings -5.55M; profit margin -3322.16%31 Mar 202630 Jun 2026: revenue 0.34M*; earnings -5.88M*; profit margin -1755.22%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2026-04-01 to 2026-06-30; USD.30 Jun 2026

30 Jun 2026 ■ Revenue 1.02M ■ Earnings -23.82M — Profit margin -2344.59%

-30.15M-2345.6%-8.36M1791.7%13.43M5928.9%35.21M10066.2%30 Jun 2023: revenue 0.29M; earnings 28.89M; profit margin 10065.16%30 Jun 202330 Jun 2024: revenue 0.33M; earnings 21.34M; profit margin 6547.24%30 Jun 202430 Jun 2025: revenue 1.34M; earnings -22.58M; profit margin -1690.34%30 Jun 202530 Jun 2026: revenue 1.02M; earnings -23.82M; profit margin -2344.59%30 Jun 2026

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$1.01(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$1.01High(m)Average(m)Low(m)2025-09-292026-09-29

Recent news

View more →

(m)

YouTube videos mentioning PLUR

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending (m).

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
(m)
Profit margin
(m)
Return on assets · 12 month
(m)
Stock compensation expense · all employees · 12 months
(m)
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
127.00
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
17.62K
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-8.18%*
Total return · month
-33.99%*
Total return · quarter
-53.02%*
Total return · half year
-68.83%*
Total return · year to date
-66.22%*
Total return · 1 year
-78.09%*
Total return · 3 years
-78.96%*
Total return · 5 years
-95.24%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
(m)
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

Pluri Inc. Overview

View more →

(m)

(m)

SEC CIK
1158780
Industry (SIC)
2836 Biological Products, (No Diagnostic Substances)
Country of operation
Israel
Business address
MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA, Israel, Israel
Fiscal year end
0630
Phone
972-74-710-7171

Similar stocks

Stock NameCountryMarket CapPE Ratio
INTENSITY THERAPEUTICS, INC. (INTS)United States$0.013B-1.08
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)United States$0.013B-1.05
Passage BIO, Inc. (PASG)United States$0.015B-0.43
IN8BIO, INC. (INAB)United States$0.012B-0.76
DYADIC INTERNATIONAL INC (DYAI)United States$0.016B
BioCardia, Inc. (BCDA)United States$0.016B
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70
TScan Therapeutics, Inc. (TCRX)United States$0.008B-1.23
Jasper Therapeutics, Inc. (JSPR)United States$0.020B-0.37
CERO THERAPEUTICS HOLDINGS, INC. (CERO)United States$0.007B